



January 28, 2026

National Stock Exchange of India Limited
Exchange Plaza, Plot No. C/1, G Block,
Bandra Kurla Complex, Bandra (E),
Mumbai - 400051.
Symbol: RAINBOW

BSE Limited
Corporate Relationship Department,
Phiroze Jeejeebhoy Towers,
Dalal Street, Mumbai - 400001.
Scrip Code: 543524

Sub: Outcome of the Board Meeting.

Ref: Disclosures under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 ("SEBI Listing Regulations").

Dear Sir/ Madam,

In furtherance to our letter dated January 21, 2026, please take note that the Board of Directors of the Company, in their meeting held today i.e., January 28, 2026, has inter-alia considered and approved the Unaudited Standalone and Consolidated Financial Results ("**Financial Results**") of the Company for the Quarter and Nine months ended December 31, 2025.

A copy of the signed Results along with Limited Review Report issued by the Statutory Auditors M/s. S.R. Batliboi & Associates LLP, Chartered Accountants, are enclosed as **Annexure - A**.

The Board Meeting commenced at 1:00 PM and concluded at 4:00 PM.

We request you to kindly take the same on record.

Thanking You,

Yours Faithfully,

For Rainbow Children's Medicare Limited

Shreya Mitra
Company Secretary and Compliance Officer

Encl.: As above

Rainbow Children's Medicare Limited

Registered Office: 8-2-120/103/1, Survey No. 403, Road No. 2, Banjara Hills, Hyderabad- 500034, Telangana

CIN:L85110TG1998PLC029914

Corporate Office: 8-2-19/1/A, Daulet Arcade, Road No. 11, Banjara Hills, Hyderabad- 500034, Telangana

info@rainbowhospitals.in **1800 2122** **www.rainbowhospitals.in**



S.R. BATLIBOI & ASSOCIATES LLP

Chartered Accountants

THE SKYVIEW 10
18th Floor, "NORTH LOBBY"
Survey No. 83/1, Raidurgam
Hyderabad - 500 032, India
Tel : +91 40 6141 6000

Independent Auditor's Review Report on the Quarterly and Year to Date Unaudited Standalone Financial Results of the Company Pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended

**Review Report to
The Board of Directors
Rainbow Children's Medicare Limited**

1. We have reviewed the accompanying statement of unaudited standalone financial results of Rainbow Children's Medicare Limited (the "Company") for the quarter ended 31 December 2025 and year to date from 01 April 2025 to 31 December 2025 (the "Statement") attached herewith, being submitted by the Company pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended (the "Listing Regulations").
2. The Company's Management is responsible for the preparation of the Statement in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34, (Ind AS 34) "Interim Financial Reporting" prescribed under Section 133 of the Companies Act, 2013 as amended, read with relevant rules issued thereunder and other accounting principles generally accepted in India and in compliance with Regulation 33 of the Listing Regulations. The Statement has been approved by the Company's Board of Directors. Our responsibility is to express a conclusion on the Statement based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410, "Review of Interim Financial Information Performed by the Independent Auditor of the Entity" issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the Statement is free of material misstatement. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.
4. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in the aforesaid Indian Accounting Standards ('Ind AS') specified under Section 133 of the Companies Act, 2013 as amended, read with relevant rules issued thereunder and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of the Listing Regulations, including the manner in which it is to be disclosed, or that it contains any material misstatement.

For S.R. BATLIBOI & ASSOCIATES LLP
Chartered Accountants
ICAI Firm registration number: 101049W/E300004

Atin Bhargava
per Atin Bhargava
Partner
Membership No.: 504777

UDIN: 265047710VDRIM8021

Place: Hyderabad
Date: 28 January 2026



Rainbow Children's Medicare Limited

CIN: L85110TG1998PLC029914

Registered Office : 8-2-120/103/1, Survey No. 403, Road No.2, Banjara Hills, Hyderabad, Telangana-500034

Tel: +91 40 4969 2244, e-mail : companysecretary@rainbowhospitals.in

Statement of Unaudited Standalone Financial Results for the quarter and year to date ended 31 December 2025

| Particulars | (Rs. in Millions except per share data) | | | | | |
|---|---|-------------------------|-------------------------|-------------------------|-------------------------|------------------|
| | Quarter ended | | | Year to date ended | | Year ended |
| | 31 December 2025 | 30 September 2025 | 31 December 2024 | 31 December 2025 | 31 December 2024 | 31 March 2025 |
| | Unaudited | Unaudited | Unaudited | Unaudited | Unaudited | Audited |
| 1. Income | | | | | | |
| a. Revenue from operations | 3,943.52 | 4,084.96 | 3,815.65 | 11,375.96 | 11,005.12 | 14,545.07 |
| b. Other income | 107.56 | 81.73 | 128.48 | 382.14 | 350.54 | 489.49 |
| Total income | 4,051.08 | 4,166.69 | 3,944.13 | 11,758.10 | 11,355.66 | 15,034.56 |
| 2. Expenses | | | | | | |
| a. Cost of materials consumed | 510.54 | 560.93 | 519.61 | 1,510.97 | 1,454.18 | 1,898.69 |
| b. Employee benefits expense | 532.67 | 532.74 | 471.95 | 1,557.77 | 1,457.61 | 1,976.08 |
| c. Finance costs | 181.70 | 173.09 | 173.51 | 528.72 | 521.79 | 695.94 |
| d. Depreciation and amortisation expense | 348.34 | 331.82 | 335.39 | 1,006.09 | 992.00 | 1,317.48 |
| e. Professional fees to doctors | 950.39 | 966.26 | 891.50 | 2,784.46 | 2,589.10 | 3,484.90 |
| f. Other expenses | 643.10 | 617.85 | 631.04 | 1,813.55 | 1,867.61 | 2,440.64 |
| Total expenses | 3,166.74 | 3,182.69 | 3,023.00 | 9,201.56 | 8,882.29 | 11,813.73 |
| 3. Profit before tax [1-2] | 884.34 | 984.00 | 921.13 | 2,556.54 | 2,473.37 | 3,220.83 |
| 4. Tax expenses | | | | | | |
| a. Current tax | 238.61 | 280.20 | 223.62 | 687.46 | 666.22 | 856.68 |
| b. Deferred tax expense/(credit) | (12.51) | (27.87) | 7.91 | (34.57) | (39.85) | (31.54) |
| c. Adjustment of tax relating to earlier periods | - | - | 19.85 | (3.46) | 16.55 | 19.84 |
| Total tax expense | 226.10 | 252.33 | 251.38 | 649.43 | 642.92 | 844.98 |
| 5. Profit after tax [3-4] | 658.24 | 731.67 | 669.75 | 1,907.11 | 1,830.45 | 2,375.85 |
| 6. Other comprehensive income | | | | | | |
| Items that will not be reclassified subsequently to the Statement of Profit or Loss | | | | | | |
| a. Re-measurement (loss) / gain on defined benefit obligation | (0.72) | (0.72) | (50.05) | (2.16) | (41.45) | (2.88) |
| b. Income tax effect | 0.18 | 0.18 | 12.60 | 0.54 | 10.43 | 0.72 |
| Other comprehensive income (net of tax) | (0.54) | (0.54) | (37.45) | (1.62) | (31.02) | (2.16) |
| 7. Total comprehensive income [5+6] | 657.70 | 731.13 | 632.30 | 1,905.49 | 1,799.43 | 2,373.69 |
| 8. Paid-up equity share capital (Face value of Rs. 10 each) | 1,015.59 | 1,015.59 | 1,015.52 | 1,015.59 | 1,015.52 | 1,015.52 |
| 9. Other equity | | | | | | 13,869.92 |
| 10. Earning per share (Face value of Rs.10 each) | | | | | | |
| a. Basic (Rs) | 6.48 | 7.20 | 6.60 | 18.78 | 18.03 | 23.40 |
| b. Diluted (Rs) | 6.48 | 7.20 | 6.60 | 18.78 | 18.03 | 23.27 |
| | <i>(Not annualised)</i> | <i>(Not annualised)</i> | <i>(Not annualised)</i> | <i>(Not annualised)</i> | <i>(Not annualised)</i> | |




Notes :

- 1 The above statement of unaudited standalone financial results of Rainbow Children's Medicare Limited ("the Company"), which have been prepared in accordance with Indian Accounting Standards ("Ind AS") prescribed under section 133 of Companies Act, 2013 ("the Act") read with relevant rules issued thereunder, other accounting principles generally accepted in India and in terms of Regulation 33 of Securities and Exchange Board of India ("SEBI") (Listing Obligations and Disclosure Requirements) Regulations, 2015 were reviewed and recommended by the Audit Committee and approved by the Board of Directors at their respective meetings held on 28 January 2026. The statutory auditors have carried out a limited review on the unaudited standalone financial results and issued an unmodified report thereon.
- 2 Pursuant to the resolutions passed by the Board of Directors on 09 February 2025 and by the Shareholders on 02 April 2025, the Company approved 'The Rainbow Children's Medicare Limited - Employee Stock Option Scheme 2025 ("ESOP 2025") in compliance with the SEBI (Share Based Employee Benefits and Sweat Equity) Regulations, 2021 ("SEBI SBEB SE Regulations"). The ESOP 2025 is for issue of employee stock options to eligible employees, which may result in an issuance of a maximum number of 1,015,000 Equity Shares. Upon exercise and payment of the exercise price, an option holder will be entitled to be allotted one equity share per employee stock option.

The Nomination and Remuneration Committee ("NRC") of the Company in its meeting held on 28 January 2026, granted 100,000 Stock options under the ESOP 2025 to its eligible employees which shall be exercisable into 100,000 equity shares having face value of Rs.10 each fully paid-up. The Exercise price per stock option shall be determined at a discount of not more than 20% on the latest available closing price of the Company's equity shares on the National Stock Exchange of India Limited, being the stock exchange with the highest trading volume, as on 27 January 2026 i.e., the trading day immediately preceding the date on which the grant of options was approved by the NRC. The Stock options shall vest after the minimum vesting period of 1 year and not later than the maximum period of 10 years from the date of grant. The vested Stock options shall be exercisable within a period of maximum of 2 years from the date of each vesting.

- 3 On 13 November 2025, the Board of Directors of the Company, based on the recommendation of the Nomination and Remuneration Committee, approved the appointment of Mr. Abrarali Dalal as Chief Executive Officer (CEO) of the Company with effect from 20 January 2026. The terms of appointment and remuneration are in accordance with the provisions of the Companies Act, 2013 and SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.
- 4 On 21 November 2025, the Government of India notified the four Labour Codes - the Code on Wages, 2019, the Industrial Relations Code, 2020, the Code on Social Security, 2020, and the Occupational Safety, Health and Working Conditions Code, 2020 - consolidating 29 existing labour laws. The Ministry of Labour & Employment published draft Central Rules and Frequently asked questions (FAQs) to enable assessment of the financial impact due to changes in regulations. The Company has estimated for incremental liability on the basis of internal assessment and the best information available, consistent with the guidance provided by the Institute of Chartered Accountants of India for employees, which is not material to the standalone financial results. The Company continues to monitor the finalisation of Central / State Rules and clarifications from the Government on other aspects of the Labour Code and would provide appropriate accounting effect on the basis of such
- 5 The Company is principally engaged in a single business segment viz., rendering medical and healthcare services. Further the business operation of the Company are concentrated in India, and hence, the Company is considered to operate only in one geographical segment.
- 6 The standalone financial results for the quarter and year to date ended 31 December 2025, are available on the BSE Limited website (URL: www.bseindia.com), the National Stock Exchange of India Limited website (URL: www.nseindia.com) and on the Company's website (URL: www.rainbowhospitals.in).



Place : Hyderabad
Date : 28 January 2026

S.R. BATLIBOI & ASSOCIATES LLP

Chartered Accountants

THE SKYVIEW 10
18th Floor, "NORTH LOBBY"
Survey No. 83/1, Raidurgam
Hyderabad - 500 032, India
Tel : +91 40 6141 6000

Independent Auditor's Review Report on the Quarterly and Year to Date Unaudited Consolidated Financial Results of the Company Pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended

**Review Report to
The Board of Directors
Rainbow Children's Medicare Limited**

1. We have reviewed the accompanying Statement of Unaudited Consolidated Financial Results of Rainbow Children's Medicare Limited (the "Holding Company") and its subsidiaries (the Holding Company and its subsidiaries together referred to as "the Group"), for the quarter ended 31 December 2025 and year to date from 01 April 2025 to 31 December 2025 (the "Statement") attached herewith, being submitted by the Holding Company pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended (the "Listing Regulations").
2. The Holding Company's Management is responsible for the preparation of the Statement in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34, (Ind AS 34) "Interim Financial Reporting" prescribed under Section 133 of the Companies Act, 2013 as amended, read with relevant rules issued thereunder and other accounting principles generally accepted in India and in compliance with Regulation 33 of the Listing Regulations. The Statement has been approved by the Holding Company's Board of Directors. Our responsibility is to express a conclusion on the Statement based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410, "Review of Interim Financial Information Performed by the Independent Auditor of the Entity" issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the Statement is free of material misstatement. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

We also performed procedures in accordance with the Master Circular issued by the Securities and Exchange Board of India under Regulation 33(8) of the Listing Regulations, to the extent applicable.

4. The Statement includes the results of the following entities:


Holding Company:
Rainbow Children's Medicare Limited

Subsidiaries:

- a. Rainbow Speciality Hospitals Private Limited
- b. Rosewalk Healthcare Private Limited
- c. Rainbow C R O Private Limited
- d. Rainbow Fertility Private Limited
- e. Rainbow Children's Hospital Private Limited
- f. Rainbow Woman & Children's Hospital Private Limited
- g. Prashanthi Medicare Private Limited (with effect from 01 July 2025)
- h. Pratiksha Women & Child Care Hospital Private Limited (with effect from 18 August 2025)

Other Consolidating Entity:
Rainbow Children's Hospital Foundation

5. Based on our review conducted and procedures performed as stated in paragraph 3 above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with



S.R. BATLIBOI & ASSOCIATES LLP

Chartered Accountants

recognition and measurement principles laid down in the aforesaid Indian Accounting Standards ('Ind AS') specified under Section 133 of the Companies Act, 2013, as amended, read with relevant rules issued thereunder and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of the Listing Regulations, including the manner in which it is to be disclosed, or that it contains any material misstatement.

6. The accompanying Statement includes the unaudited interim financial results, in respect of 2 subsidiaries, whose unaudited interim financial results include total revenues of Rs 217.21 million and Rs 599.74 million, total net profit after tax of Rs. 30.54 million and Rs. 65.68 million, total comprehensive income of Rs. 30.94 million and Rs. 66.85 million, for the quarter ended 31 December 2025 and the year to date from 01 April 2024 to 31 December 2025 respectively, as considered in the Statement which have been reviewed by their respective independent auditors.

The independent auditor's reports on interim financial results of these entities have been furnished to us by the Management and our conclusion on the Statement, in so far as it relates to the amounts and disclosures in respect of these subsidiaries is based solely on the report of such auditors and procedures performed by us as stated in paragraph 3 above.

7. The accompanying Statement includes unaudited interim financial results in respect of 4 subsidiaries, whose interim financial results reflect total revenues of Rs Nil million and Rs 1.59 million, total net profit after tax of Rs. 0.56 million and Rs. 2.85 million, total comprehensive income of Rs. 0.56 million and Rs. 2.85 million, for the quarter ended 31 December 2025 and the year to date from 01 April 2024 to 31 December 2025 respectively.

The unaudited interim financial results of these subsidiaries have not been reviewed by their auditors and have been approved and furnished to us by the Management and our conclusion on the Statement, in so far as it relates to the affairs of these subsidiaries, is based solely on such unaudited interim financial results. According to the information and explanations given to us by the Management, these interim financial results are not material to the Group.

Our conclusion on the Statement in respect of matters stated in para 6 and 7 is not modified with respect to our reliance on the work done and the reports of the other auditors and the financial results certified by the Management.

For S.R. Batliboi & Associates LLP

Chartered Accountants


ICAI Firm registration number: 101049W/E300004

per Atin Bhargava

Partner

Membership No.: 504777

UDIN: 26504777LAXVN2926



Place: Hyderabad

Date: 28 January 2026

Rainbow Children's Medicare Limited

CIN: L85110TG1998PLC029914

Registered Office : 8-2-120/103/1, Survey No. 403, Road No.2, Banjara Hills, Hyderabad, Telangana-500034

Tel: +91 40 4969 2244, e-mail : companysecretary@rainbowhospitals.in

Statement of Unaudited Consolidated Financial Results for the quarter and year to date ended 31 December 2025

(Rs. in Million except per share data)

| Particulars | Quarter ended | | | Year to date ended | | Year ended 31 March 2025 |
|---|------------------|-------------------|------------------|--------------------|------------------|-----------------------------|
| | 31 December 2025 | 30 September 2025 | 31 December 2024 | 31 December 2025 | 31 December 2024 | |
| | Unaudited | Unaudited | Unaudited | Unaudited | Unaudited | |
| 1. Income | | | | | | |
| a. Revenue from operations | 4,454.48 | 4,447.99 | 3,980.82 | 12,431.76 | 11,457.59 | 15,158.66 |
| b. Other income | 105.13 | 81.95 | 132.74 | 387.24 | 364.81 | 510.08 |
| Total income | 4,559.61 | 4,529.94 | 4,113.56 | 12,819.00 | 11,822.40 | 15,668.74 |
| 2. Expenses | | | | | | |
| a. Cost of materials consumed | 603.34 | 622.14 | 537.28 | 1,700.46 | 1,478.79 | 1,949.20 |
| b. Employee benefits expense | 600.60 | 587.80 | 493.06 | 1,704.60 | 1,520.51 | 2,063.67 |
| c. Finance costs | 201.95 | 188.49 | 180.70 | 571.22 | 543.34 | 724.55 |
| d. Depreciation and amortisation expense | 396.00 | 358.41 | 352.34 | 1,096.28 | 1,042.77 | 1,384.40 |
| e. Professional fees to doctors | 1,080.62 | 1,063.19 | 943.70 | 3,061.39 | 2,745.60 | 3,690.21 |
| f. Other expenses | 700.16 | 686.21 | 663.21 | 1,970.67 | 1,961.07 | 2,556.70 |
| Total expenses | 3,582.67 | 3,506.24 | 3,170.29 | 10,104.62 | 9,292.08 | 12,368.73 |
| 3. Profit before tax [1-2] | 976.94 | 1,023.70 | 943.27 | 2,714.38 | 2,530.32 | 3,300.01 |
| 4. Tax expenses | | | | | | |
| a. Current tax | 238.99 | 292.64 | 228.10 | 706.45 | 678.57 | 873.08 |
| b. Deferred tax expense/(credit) | (1.02) | (25.18) | 5.91 | (21.87) | (41.54) | (35.19) |
| c. Adjustment of tax relating to earlier periods | - | - | 19.85 | (3.46) | 16.55 | 19.85 |
| Total tax expense | 237.97 | 267.46 | 253.86 | 681.12 | 653.58 | 857.74 |
| 5. Profit after tax [3-4] | 738.97 | 756.24 | 689.41 | 2,033.26 | 1,876.74 | 2,442.27 |
| 6. Other comprehensive income | | | | | | |
| Items that will not be reclassified subsequently to the Statement of Profit or Loss | | | | | | |
| a. Re-measurement (loss)/gain on defined benefit obligation | (0.24) | (0.25) | (49.92) | (0.73) | (41.07) | (0.98) |
| b. Income tax effect | 0.10 | 0.09 | 12.59 | 0.28 | 10.41 | 0.37 |
| Other comprehensive income (net of tax) | (0.14) | (0.16) | (37.33) | (0.45) | (30.66) | (0.61) |
| 7. Total comprehensive income [5+6] | 738.83 | 756.08 | 652.08 | 2,032.81 | 1,846.08 | 2,441.66 |
| Profit after tax attributable to | | | | | | |
| Owners of the Company | 725.31 | 752.50 | 686.87 | 2,012.80 | 1,870.89 | 2,434.24 |
| Non-controlling interests | 13.66 | 3.74 | 2.54 | 20.46 | 5.85 | 8.03 |
| Profit after tax | 738.97 | 756.24 | 689.41 | 2,033.26 | 1,876.74 | 2,442.27 |
| Other comprehensive income attributable to | | | | | | |
| Owners of the Company | (0.19) | (0.18) | (37.33) | (0.58) | (30.67) | (0.83) |
| Non-controlling interests | 0.04 | 0.02 | 0.00 | 0.13 | 0.01 | 0.22 |
| Other comprehensive income | (0.15) | (0.16) | (37.33) | (0.45) | (30.66) | (0.61) |
| Total comprehensive income attributable to | | | | | | |
| Owners of the Company | 725.12 | 752.32 | 649.54 | 2,012.22 | 1,840.22 | 2,433.41 |
| Non-controlling interests | 13.70 | 3.76 | 2.54 | 20.59 | 5.86 | 8.25 |
| Total comprehensive income | 738.82 | 756.08 | 652.08 | 2,032.81 | 1,846.08 | 2,441.66 |
| 8. Paid-up equity share capital (Face value of Rs. 10 each) | | | | | | |
| 9. Other equity | | | | | | |
| 10. Earning per share (Face value of Rs.10 each) | | | | | | |
| a. Basic (Rs) | 7.14 | 7.41 | 6.76 | 19.82 | 18.43 | 23.97 |
| b. Diluted (Rs) | 7.14 | 7.41 | 6.76 | 19.82 | 18.43 | 23.84 |
| | (Not annualised) | (Not annualised) | (Not annualised) | (Not annualised) | (Not annualised) | |



Notes :

- 1 The above statement of unaudited consolidated financial results of Rainbow Children's Medicare Limited ("the Company"), its subsidiaries and other consolidating entity (the Company, its subsidiaries and other consolidating entity together referred to as "the Group") which have been prepared in accordance with Indian Accounting Standards ("Ind AS") prescribed under section 133 of Companies Act, 2013 ("the Act") read with relevant rules issued thereunder, other accounting principles generally accepted in India and guidelines issued by the Securities and Exchange Board of India ("SEBI") were reviewed and recommended by the Audit Committee and approved by the Board of Directors at their respective meetings held on 28 January 2026. The statutory auditors have carried out a limited review on the unaudited consolidated financial results and issued an unmodified report thereon.
- 2 Pursuant to the resolutions passed by the Board of Directors on 09 February 2025 and by the Shareholders on 02 April 2025, the Company approved 'The Rainbow Children's Medicare Limited - Employee Stock Option Scheme 2025 ("ESOP 2025") in compliance with the SEBI (Share Based Employee Benefits and Sweat Equity) Regulations, 2021 ("SEBI SBEB SE Regulations"). The ESOP 2025 is for issue of employee stock options to eligible employees, which may result in an issuance of a maximum number of 1,015,000 Equity Shares. Upon exercise and payment of the exercise price, an option holder will be entitled to be allotted one equity share per employee stock option.

The Nomination and Remuneration Committee ("NRC") of the Company in its meeting held on 28 January 2026, granted 100,000 Stock options under the ESOP 2025 to its eligible employees which shall be exercisable into 100,000 equity shares having face value of Rs.10 each fully paid-up. The Exercise price per stock option shall be determined at a discount of not more than 20% on the latest available closing price of the Company's equity shares on the National Stock Exchange of India Limited, being the stock exchange with the highest trading volume, as on 27 January 2026 i.e., the trading day immediately preceding the date on which the grant of options was approved by the NRC. The Stock options shall vest after the minimum vesting period of 1 year and not later than the maximum period of 10 years from the date of grant. The vested Stock options shall be exercisable within a period of maximum of 2 years from the date of each vesting.

- 3 On 13 November 2025, the Board of Directors of the Company, based on the recommendation of the Nomination and Remuneration Committee, approved the appointment of Mr. Abrarali Dalal as Chief Executive Officer (CEO) of the Group with effect from 20 January 2026. The terms of appointment and remuneration are in accordance with the provisions of the Companies Act, 2013 and SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.
- 4 On 21 November 2025, the Government of India notified the four Labour Codes - the Code on Wages, 2019, the Industrial Relations Code, 2020, the Code on Social Security, 2020, and the Occupational Safety, Health and Working Conditions Code, 2020 - consolidating 29 existing labour laws. The Ministry of Labour & Employment published draft Central Rules and Frequently asked questions (FAQs) to enable assessment of the financial impact due to changes in regulations. The Group has estimated for incremental liability on the basis of internal assessment and the best information available, consistent with the guidance provided by the Institute of Chartered Accountants of India for employees, which is not material to the consolidated financial results. The Group continues to monitor the finalisation of Central / State Rules and clarifications from the Government on other aspects of the Labour Code and would provide appropriate accounting effect on the basis of such developments as needed.
- 5 The Group is principally engaged in a single business segment viz., rendering medical and healthcare services. Further the business operation of the group are concentrated in India, and hence, the group is considered to operate only in one geographical segment.
- 6 The consolidated financial results for the quarter and year to date ended 31 December 2025, are available on the BSE Limited website (URL: www.bseindia.com), the National Stock Exchange of India Limited website (URL: www.nseindia.com) and on the Company's website (URL: www.rainbowhospitals.in).
- 7 The unaudited consolidated financial results include the financial results of Rainbow Children's Medicare Limited and the financial results of its subsidiaries, Rainbow C R O Private Limited, Rainbow Fertility Private Limited, Rainbow Women & Children's Hospital Private Limited, Rainbow Speciality Hospitals Private Limited, Rosewalk Healthcare Private Limited, Rainbow Children's Hospital Private Limited, Prashanthi Medicare Private Limited, Pratiksha Women & Child Care Hospital Private Limited and its other consolidating entity, Rainbow Children's Hospital Foundation.

Place : Hyderabad
Date : 28 January 2026



for and on behalf of the Board of Directors of
Rainbow Children's Medicare Limited
HYDERABAD
Dr. Ramesh Kancharla
Chairman and Managing Director
DIN: 00212270